Cargando…

Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features

The novel coronavirus pandemic has emerged as one of the significant medical-health challenges of the current century. The World Health Organization has named this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first detection of SARS-CoV-2 in November 2019 in Wuha...

Descripción completa

Detalles Bibliográficos
Autores principales: Rommasi, Foad, Nasiri, Mohammad Javad, Mirsaeidi, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747854/
https://www.ncbi.nlm.nih.gov/pubmed/35013850
http://dx.doi.org/10.1007/s11010-021-04325-9
_version_ 1784630929677877248
author Rommasi, Foad
Nasiri, Mohammad Javad
Mirsaeidi, Mehdi
author_facet Rommasi, Foad
Nasiri, Mohammad Javad
Mirsaeidi, Mehdi
author_sort Rommasi, Foad
collection PubMed
description The novel coronavirus pandemic has emerged as one of the significant medical-health challenges of the current century. The World Health Organization has named this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first detection of SARS-CoV-2 in November 2019 in Wuhan, China, physicians, researchers, and others have made it their top priority to find drugs and cures that can effectively treat patients and reduce mortality rates. The symptoms of Coronavirus Disease 2019 (COVID-19) include fever, dry cough, body aches, and anosmia. Various therapeutic compounds have been investigated and applied to mitigate the symptoms in COVID-19 patients and cure the disease. Degenerative virus analyses of the infection incidence and COVID-19 have demonstrated that SARS-CoV-2 penetrates the pulmonary alveoli's endothelial cells through Angiotensin-Converting Enzyme 2 (ACE2) receptors on the membrane, stimulates various signaling pathways and causes excessive secretion of cytokines. The continuous triggering of the innate and acquired immune system, as well as the overproduction of pro-inflammatory factors, cause a severe condition in the COVID-19 patients, which is called "cytokine storm". It can lead to acute respiratory distress syndrome (ARDS) in critical patients. Severe and critical COVID-19 cases demand oxygen therapy and mechanical ventilator support. Various drugs, including immunomodulatory and immunosuppressive agents (e.g., monoclonal antibodies (mAbs) and interleukin antagonists) have been utilized in clinical trials. However, the studies and clinical trials have documented diverging findings, which seem to be due to the differences in these drugs' possible mechanisms of action. These drugs' mechanism of action generally includes suppressing or modulating the immune system, preventing the development of cytokine storm via various signaling pathways, and enhancing the blood vessels' diameter in the lungs. In this review article, multiple medications from different drug families are discussed, and their possible mechanisms of action are also described.
format Online
Article
Text
id pubmed-8747854
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-87478542022-01-11 Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features Rommasi, Foad Nasiri, Mohammad Javad Mirsaeidi, Mehdi Mol Cell Biochem Article The novel coronavirus pandemic has emerged as one of the significant medical-health challenges of the current century. The World Health Organization has named this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first detection of SARS-CoV-2 in November 2019 in Wuhan, China, physicians, researchers, and others have made it their top priority to find drugs and cures that can effectively treat patients and reduce mortality rates. The symptoms of Coronavirus Disease 2019 (COVID-19) include fever, dry cough, body aches, and anosmia. Various therapeutic compounds have been investigated and applied to mitigate the symptoms in COVID-19 patients and cure the disease. Degenerative virus analyses of the infection incidence and COVID-19 have demonstrated that SARS-CoV-2 penetrates the pulmonary alveoli's endothelial cells through Angiotensin-Converting Enzyme 2 (ACE2) receptors on the membrane, stimulates various signaling pathways and causes excessive secretion of cytokines. The continuous triggering of the innate and acquired immune system, as well as the overproduction of pro-inflammatory factors, cause a severe condition in the COVID-19 patients, which is called "cytokine storm". It can lead to acute respiratory distress syndrome (ARDS) in critical patients. Severe and critical COVID-19 cases demand oxygen therapy and mechanical ventilator support. Various drugs, including immunomodulatory and immunosuppressive agents (e.g., monoclonal antibodies (mAbs) and interleukin antagonists) have been utilized in clinical trials. However, the studies and clinical trials have documented diverging findings, which seem to be due to the differences in these drugs' possible mechanisms of action. These drugs' mechanism of action generally includes suppressing or modulating the immune system, preventing the development of cytokine storm via various signaling pathways, and enhancing the blood vessels' diameter in the lungs. In this review article, multiple medications from different drug families are discussed, and their possible mechanisms of action are also described. Springer US 2022-01-11 2022 /pmc/articles/PMC8747854/ /pubmed/35013850 http://dx.doi.org/10.1007/s11010-021-04325-9 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Rommasi, Foad
Nasiri, Mohammad Javad
Mirsaeidi, Mehdi
Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features
title Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features
title_full Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features
title_fullStr Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features
title_full_unstemmed Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features
title_short Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features
title_sort immunomodulatory agents for covid-19 treatment: possible mechanism of action and immunopathology features
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747854/
https://www.ncbi.nlm.nih.gov/pubmed/35013850
http://dx.doi.org/10.1007/s11010-021-04325-9
work_keys_str_mv AT rommasifoad immunomodulatoryagentsforcovid19treatmentpossiblemechanismofactionandimmunopathologyfeatures
AT nasirimohammadjavad immunomodulatoryagentsforcovid19treatmentpossiblemechanismofactionandimmunopathologyfeatures
AT mirsaeidimehdi immunomodulatoryagentsforcovid19treatmentpossiblemechanismofactionandimmunopathologyfeatures